Although EGFR-mutant lung adenocarcinoma patients with early onset LM reserve the opportunity to control their LM through targeted therapy, our results suggest that early onset LM independently predicts a poor outcome. The gene discussed is EGFR; the disease is lung adenocarcinoma.